Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174397 | 0.81 | FFAR3 (0.32) | — | |
| Hydrochloric Acid SCHEMBL2198959 | 0.79 | FFAR3 (0.31) | — | |
| Hydrochloric Acid SCHEMBL4359360 | 0.79 | FFAR3 (0.31) | — | |
| SCHEMBL7387847 | 0.77 | NPSR1 (0.37) | CYP3A4MEN1KMT2AITGB1ITGA4 | |
| SCHEMBL4589011 | 0.74 | CYP2C19 (0.33) | — | |
| SCHEMBL741463 | 0.74 | — | — | |
| SCHEMBL27454182 | 0.72 | GLS (0.46) | CYP3A4SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL24471428 | 0.70 | GRM4 (0.41) | MEN1KMT2A | |
| SCHEMBL5313434 | 0.67 | CYP3A4 (0.30) | CYP3A4SMN1; SMN2 | |
| SCHEMBL628215 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645516-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019001420-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |